(A) qPCR (top) and western blot (bottom) showing the expression of PLOD2 in MIHA and 5 HCC cell lines. (B) The efficiency of PLOD2 KD was measured by real-time PCR (top) and western blotting (bottom) assays. ***p<0.001. (C) KD of PLOD2 decreased Huh7 and MHCC-97H cell migration. ***p<0.001. (D) KD of PLOD2 decreased Huh7 and MHCC-97H cell invasion. **p<0.01, ***p<0.001. (E) KD of PLOD2 impaired the scratch wound healing ability of Huh7 and MHCC-97H cells. (F) KD of PLOD2 inhibited Huh7 and MHCC-97H cell proliferation. **p<0.01, ***p<0.001. (G, H) KD of PLOD2 significantly inhibited tumor size and growth. ***p<0.001. (I) KD of PLOD2 significantly inhibited tumor weight. ***p<0.001. (J) Representative IHC staining images showing that the expression of PLOD2 and Ki67 were significantly decreased in the KD groups. (K) KD of PLOD2 significantly suppressed the expression of Ki67 in a nude mouse model established by injection of Huh7 cells into the right flank (n=6). ***p<0.001. (L) KD of PLOD2 significantly suppressed lung metastasis in a nude mouse model established by injection of Huh7 cells through the tail vein (n=4). **p<0.01. HCC, hepatocellular carcinoma; IHC, immunohistochemical; KD, knockdown; PLOD2, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2.